This clinical trial is focused on studying the effects of a medication called filgotinib in children and teenagers who have a condition known as ulcerative colitis. Ulcerative colitis is a disease that causes inflammation and sores in the lining of the large intestine, which can lead to symptoms like abdominal pain and diarrhea. The medication being tested, filgotinib, is taken orally in the form of film-coated tablets or mini-tablets. In this study, the medication is also referred to by its code name, GLPG0634.

The purpose of the study is to evaluate how effective filgotinib is in helping children and teenagers achieve and maintain remission, which means reducing or eliminating the symptoms of ulcerative colitis. The study will involve participants taking the medication over a period of time, with regular check-ups to monitor their health and any changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance.

Throughout the study, researchers will assess various aspects of the participants’ health, including any side effects they may experience and changes in their growth and development. The study aims to gather information on how well filgotinib works in young people with ulcerative colitis and how safe it is for them to use. The study is expected to continue until 2027, with the recruitment of participants starting in 2024.